Literature DB >> 19351236

Efficacy and safety of intranasal xylometazoline and ipratropium in patients with common cold.

P Graf1, R Eccles, S Chen.   

Abstract

BACKGROUND: Many over-the-counter medications are available to treat common cold nasal symptoms, but patients may be unsure which one to use.
METHODS: This review assesses two widely used intranasal treatments for nasal congestion and rhinorrhea in the common cold: xylometazoline hydrochloride and ipratropium bromide.
RESULTS: Xylometazoline quickly and effectively relieves nasal congestion, while ipratropium is effective at reducing rhinorrhea. When used in combination, a novel approach to treatment, nasal congestion and rhinorrhea are treated simultaneously, providing effective relief from two of the most troublesome symptoms of the common cold Both drugs are well tolerated, with only mild to moderate, nasal-related side effects.
CONCLUSIONS: The efficacy and safety of the combination product suggest that it should be used first-line in the symptomatic relief of nasal congestion and rhinorrhea, before the use of oral treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351236     DOI: 10.1517/14656560902783051

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Intranasal ipratropium bromide for the common cold.

Authors:  Zaina H AlBalawi; Sahar S Othman; Khalid Alfaleh
Journal:  Cochrane Database Syst Rev       Date:  2013-06-19

Review 2.  Inhaled anti-cholinergics for prolonged non-specific cough in children.

Authors:  A B Chang; M McKean; P Morris
Journal:  Cochrane Database Syst Rev       Date:  2004

3.  A comparison of the effects of epinephrine and xylometazoline in decreasing nasal bleeding during nasotracheal intubation.

Authors:  Jaegyok Song
Journal:  J Dent Anesth Pain Med       Date:  2017-12-28

Review 4.  Immune Function and Micronutrient Requirements Change over the Life Course.

Authors:  Silvia Maggini; Adeline Pierre; Philip C Calder
Journal:  Nutrients       Date:  2018-10-17       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.